Sanofi SA (EPA:SAN)‘s stock had its “neutral” rating reiterated by equities researchers at J P Morgan Chase & Co in a research report issued to clients and investors on Friday.

Several other research analysts have also issued reports on SAN. Berenberg Bank set a €97.00 ($115.48) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Thursday, May 11th. Jefferies Group LLC set a €92.00 ($109.52) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Friday, May 12th. Goldman Sachs Group, Inc. (The) set a €82.00 ($97.62) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Wednesday, May 24th. Morgan Stanley set a €91.00 ($108.33) price objective on Sanofi SA and gave the stock a “buy” rating in a research note on Tuesday, June 6th. Finally, UBS AG set a €82.00 ($97.62) price objective on Sanofi SA and gave the stock a “neutral” rating in a research note on Wednesday, June 14th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company. Sanofi SA currently has an average rating of “Hold” and a consensus target price of €88.06 ($104.84).

Sanofi SA (SAN) opened at 81.99 on Friday. The stock’s 50 day moving average is €25.48 and its 200 day moving average is €25.74. Sanofi SA has a one year low of €62.50 and a one year high of €92.97. The firm has a market cap of €102.96 billion and a P/E ratio of 11.44.

ILLEGAL ACTIVITY NOTICE: “Sanofi SA (SAN) Earns “Neutral” Rating from J P Morgan Chase & Co” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/08/sanofi-sa-san-earns-neutral-rating-from-j-p-morgan-chase-co.html.

Sanofi SA Company Profile

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Analyst Recommendations for Sanofi SA (EPA:SAN)

Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.